Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
In the development of HIV vaccines, improving immunogenicity while maintaining safety is critical. Route of administration can be an important factor.This multicenter, open-label, randomized trial, HVTN 069, compared routes of administration on safety and immunogenicity of a DNA vaccine prime given...
Main Authors: | Beryl A Koblin, Martin Casapia, Cecilia Morgan, Li Qin, Zhixue Maggie Wang, Olivier D Defawe, Lindsey Baden, Paul Goepfert, Georgia D Tomaras, David C Montefiori, M Juliana McElrath, Lilian Saavedra, Chuen-Yen Lau, Barney S Graham, NIAID HIV Vaccine Trials Network |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3171485?pdf=render |
Similar Items
-
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
by: Laurence Peiperl, et al.
Published: (2010-10-01) -
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
by: Spyros A Kalams, et al.
Published: (2012-01-01) -
Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
by: Florian Kreppel, et al.
Published: (2021-02-01) -
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
by: Goepfert P, et al.
Published: (2012-09-01) -
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
by: Susan P Buchbinder, et al.
Published: (2017-01-01)